India's Marck gets FDA Warning Letter

Share this article:

The FDA has issued yet another warning letter to a drug manufacturer in India.

Regulatory Focus reports that inspectors of Marck Biosciences found an array of problems during an October-November 2013 inspection, including mold near a sterile area that was so bad “the room had ‘partially caved in.'”

This is in addition to finding dead insects and dead frogs. Inspectors found paperwork equally poor, uncovering what amounted to two sets of books, resulting in mismatches such as official reports indicating that 18 units of a drug batch failed to hit quality control marks, while unofficial records—kept on scrap paper—indicated it was really more like 200 units. Employees also told inspectors they had falsified reports.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.